AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Victory Square Technologies Inc.
Video analysis: VSQTF
All videosNo video analysis for this stock yet. Request one from our team.
News: VSQTF
Victory Square Technologies Reports First-Half 2026 Revenue of $53.0 Million and Net Income of $6.5 Million
Q2 revenue increases 421% year-over-year to $28.0 million; cash reaches $20.2 million and working capital increases to $34.5 million VANCOUVER, BC, Sept. 1, 2026 /PRNewswire/ -- Victory Square Technologies Inc. ("Victory Square", "VST" or the "Company") (CSE: VST) (OTCQX: VSQTF) (FWB: 6F6), a venture builder focused on healthcare infrastructure, digital health, artificial intelligence and emerging technology platforms, today announced its financial results for the three and six months ended June 30, 2026, and provided an update on key portfolio developments.
Hydreight Reports Record Q2 2026 Revenue of $28.0 Million, Net Income of $2.5 Million and Adjusted EBITDA of $3.2 Million
Hydreight Reports Record Q2 2026 Revenue of $28.0 Million, Net Income of $2.5 Million and Adjusted EBITDA of $3.2 Million PR News
Hydreight Reports Record Q2 2026 Revenue of $28.0 Million, Net Income of $2.5 Million and Adjusted EBITDA of $3.2 Million
Revenue increased 421% year-over-year as Hydreight delivered its strongest revenue quarter to date, with continued sequential growth in revenue and gross profit while maintaining strong profitability Q2 2026 Highlights Revenue of $28.0 million, an increase of 421% from $5.4 million in Q2 2025 and approximately 12.5% from Q1 2026 Gross profit of $5.4 million, an increase of 182% from $1.9 million in Q2 2025 and approximately 7% quarter over quarter Net income of $2.5 million, compared with $0.05 million in Q2 2025 Adjusted EBITDA¹ of $3.2 million, compared with $0.2 million in Q2 2025 Six-month revenue of $53.0 million, an increase of 434% year-over-year Six-month net income of $5.1 million Working capital of $35.0 million at June 30, 2026 Cash of $20.0 million at June 30, 2026 VANCOUVER, BC and LAS VEGAS, Aug. 31, 2026 /PRNewswire/ -- Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a U.S.-focused digital health infrastructure platform, is pleased to report its financial results for the three and six months ended June 30, 2026. All figures are in Canadian dollars unless otherwise stated.
Hydreight Technologies Announces Timing of Q2 2026 Financial Results and Investor Webcast Featuring Live Analyst Q&A
VANCOUVER, BC and LAS VEGAS, Aug. 27, 2026 /PRNewswire/ -- Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a rapidly growing digital health platform and provider of compliant healthcare infrastructure across the United States, today announced that the Company will release its second quarter 2026 financial results after market close on Monday, August 31, 2026. Management will host an investor webcast and conference call on Tuesday, September 1, 2026 at 6:00 a.m.
Hydreight to Participate in Canaccord Genuity's 46th Annual Growth Conference in Boston
VANCOUVER, BC, Aug. 6, 2026 /PRNewswire/ -- Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) ("Hydreight" or the "Company"), a healthcare technology company operating a nationwide physician-supervised healthcare platform with a network of more than 300 licensed physicians, more than 3,000 licensed nurses, and pharmacy partners serving all 50 U.S. states, is pleased to announce that it has been invited to participate in Canaccord Genuity's 46th Annual Growth Conference, taking place August 11–13, 2026, at the InterContinental Boston in Boston, Massachusetts. The Canaccord Genuity Growth Conference is one of North America's premier institutional investor conferences, bringing together leading public and private growth companies with institutional investors from around the world across the technology, healthcare & life sciences, sustainability, industrials, and consumer sectors.
Victory Square Provides Update on Hydreight and Healthcare Investments Following FDA Advisory Committee Recommendations on Peptide-Related Bulk Drug Substances
VANCOUVER, BC, July 29, 2026 /PRNewswire/ -- Victory Square Technologies Inc. ("Victory Square", "VST" or the "Company") (CSE: VST) (OTCQX: VSQTF) (FWB: 6F6) is providing shareholders with an update following today's news release issued by Hydreight Technologies Inc. ("Hydreight") regarding the recommendations of the U.S. Food and Drug Administration ("FDA") Pharmacy Compounding Advisory Committee ("PCAC") relating to certain peptide-related bulk drug substances. Victory Square is Hydreight's largest shareholder, holding 23,891,515 common shares, representing approximately 44.5% of Hydreight's issued common shares.
Hydreight Provides Business Update on its Peptide Healthcare Platform Following Recent FDA Advisory Committee Recommendations
VANCOUVER, BC and LAS VEGAS, July 29, 2026 /PRNewswire/ -- Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV: NURS) (FSE: SO6) (OTCQB: HYDTF), a digital health platform connecting healthcare providers, pharmacies and patients across the United States, today provided an update on its peptide healthcare platform following the recent recommendations of the U.S. Food and Drug Administration's ("FDA") Pharmacy Compounding Advisory Committee ("PCAC"). During its July 23–24, 2026 meeting, the PCAC recommended that six peptide-related bulk drug substances—BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon—be considered for inclusion on the FDA's Section 503A Bulks List.
